

APPENDIX A
"CLEAN" VERSION OF EACH PARAGRAPH/SECTION/CLAIM
37 C.F.R. § 1.121(b)(ii) AND (c)(i)

CLAIMS (with indication of amended or new):

A (Amended) 3. The use according to claim 1, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.

(Amended) 4. The use according to claim 1, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

(Amended) 5. The use according to claim 1, wherein the chemokine receptor antagonist is Met-RANTES.

B (Amended) 6. The use according to claim 1, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.

(Amended) 7. The use according to claim 1, wherein the cyclosporin is cyclosporin A.

(Amended) 8. The use according to claim 1, for treating or preventing renal allograft transplantation.

(Amended) 11. The pharmaceutical composition according to claim 9, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.

(Amended) 12. The pharmaceutical composition according to claim 9, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

(Amended) 13. The pharmaceutical composition according to claim 9, wherein the chemokine receptor antagonist is Met-RANTES.

(Amended) 14. The pharmaceutical composition according to claim 9, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.

(Amended) 15. The pharmaceutical composition according to claim 10, wherein the cyclosporin is cyclosporin A.

(Amended) 16. The pharmaceutical composition according to claim 9, for treating or preventing renal allograft transplantation.